La raniditina nella prevenzione dei danni gastro-duodenali da polichemioterapia antiblastica

Translated title of the contribution: Ranitidine in the prevention of gastroduodenal damage during antiblastic polychemotherapy

A. D'Agata, M. Berretta, S. Sensi, S. Berretta

Research output: Contribution to journalArticle

Abstract

Background. The authors report their personal experience of the use of ranitidine in the prevention of gastroduodenal damage induced by antiblastic drugs during antiblastic polychemotherapy. Methods. A heterogeneous group of cancer patients was monitored from January 1984 to December 1999 (293 males and 204 females), aged between 36 and 80 years old, all of whom were undergoing antineoplastic polychemotherapy. Preventive treatment with ranitidine at a dose of 300 mg/die per os in a single evening bolus continued through the entire period of antiblastic treatment ranging from a minimum of six months to one year or more. The study was carried out in the General Surgery Department of Valdichiana Senese, Local Health Unit 7 in Siena and in the Department of Surgical Oncology at the University of Catania. The study consisted of a clinical and instrumental follow-up using esophagogastroduodenoscopy at the time patients were enrolled and at 3, 6 and 12 months, or at the end of treatment if longer. Results. Ranitidine was useful and could significantly reduce the harmful gastric effects of antiblastic drugs, as has been extensively shown by the literature. These drugs can lead to the suspension of treatment owing to intolerance or even death. In this study ranitidine reduced the damaging effects on the upper digestive tract in respectively 78% of the cases treated compared to 22% of non-responders. Conclusions. The action of ranitidine made antiblastic treatment more acceptable by mitigating or even blocking the damaging effects on the stomach and duodenum, leading to an improved quality of life for cancer patients.

Original languageItalian
Pages (from-to)155-164
Number of pages10
JournalMinerva Gastroenterologica e Dietologica
Volume46
Issue number3
Publication statusPublished - 2000

Fingerprint

Ranitidine
Combination Drug Therapy
Stomach
Pharmaceutical Preparations
Digestive System Endoscopy
Therapeutics
Duodenum
Antineoplastic Agents
Gastrointestinal Tract
Neoplasms
Suspensions
Quality of Life
Health

ASJC Scopus subject areas

  • Gastroenterology

Cite this

La raniditina nella prevenzione dei danni gastro-duodenali da polichemioterapia antiblastica. / D'Agata, A.; Berretta, M.; Sensi, S.; Berretta, S.

In: Minerva Gastroenterologica e Dietologica, Vol. 46, No. 3, 2000, p. 155-164.

Research output: Contribution to journalArticle

@article{add46698a5414c2598691df506e1805b,
title = "La raniditina nella prevenzione dei danni gastro-duodenali da polichemioterapia antiblastica",
abstract = "Background. The authors report their personal experience of the use of ranitidine in the prevention of gastroduodenal damage induced by antiblastic drugs during antiblastic polychemotherapy. Methods. A heterogeneous group of cancer patients was monitored from January 1984 to December 1999 (293 males and 204 females), aged between 36 and 80 years old, all of whom were undergoing antineoplastic polychemotherapy. Preventive treatment with ranitidine at a dose of 300 mg/die per os in a single evening bolus continued through the entire period of antiblastic treatment ranging from a minimum of six months to one year or more. The study was carried out in the General Surgery Department of Valdichiana Senese, Local Health Unit 7 in Siena and in the Department of Surgical Oncology at the University of Catania. The study consisted of a clinical and instrumental follow-up using esophagogastroduodenoscopy at the time patients were enrolled and at 3, 6 and 12 months, or at the end of treatment if longer. Results. Ranitidine was useful and could significantly reduce the harmful gastric effects of antiblastic drugs, as has been extensively shown by the literature. These drugs can lead to the suspension of treatment owing to intolerance or even death. In this study ranitidine reduced the damaging effects on the upper digestive tract in respectively 78{\%} of the cases treated compared to 22{\%} of non-responders. Conclusions. The action of ranitidine made antiblastic treatment more acceptable by mitigating or even blocking the damaging effects on the stomach and duodenum, leading to an improved quality of life for cancer patients.",
keywords = "Antineoplastic agents therapeutic use, Antineoplastic agents, combined, Ranitidine",
author = "A. D'Agata and M. Berretta and S. Sensi and S. Berretta",
year = "2000",
language = "Italian",
volume = "46",
pages = "155--164",
journal = "Minerva Gastroenterologica",
issn = "0026-4776",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - La raniditina nella prevenzione dei danni gastro-duodenali da polichemioterapia antiblastica

AU - D'Agata, A.

AU - Berretta, M.

AU - Sensi, S.

AU - Berretta, S.

PY - 2000

Y1 - 2000

N2 - Background. The authors report their personal experience of the use of ranitidine in the prevention of gastroduodenal damage induced by antiblastic drugs during antiblastic polychemotherapy. Methods. A heterogeneous group of cancer patients was monitored from January 1984 to December 1999 (293 males and 204 females), aged between 36 and 80 years old, all of whom were undergoing antineoplastic polychemotherapy. Preventive treatment with ranitidine at a dose of 300 mg/die per os in a single evening bolus continued through the entire period of antiblastic treatment ranging from a minimum of six months to one year or more. The study was carried out in the General Surgery Department of Valdichiana Senese, Local Health Unit 7 in Siena and in the Department of Surgical Oncology at the University of Catania. The study consisted of a clinical and instrumental follow-up using esophagogastroduodenoscopy at the time patients were enrolled and at 3, 6 and 12 months, or at the end of treatment if longer. Results. Ranitidine was useful and could significantly reduce the harmful gastric effects of antiblastic drugs, as has been extensively shown by the literature. These drugs can lead to the suspension of treatment owing to intolerance or even death. In this study ranitidine reduced the damaging effects on the upper digestive tract in respectively 78% of the cases treated compared to 22% of non-responders. Conclusions. The action of ranitidine made antiblastic treatment more acceptable by mitigating or even blocking the damaging effects on the stomach and duodenum, leading to an improved quality of life for cancer patients.

AB - Background. The authors report their personal experience of the use of ranitidine in the prevention of gastroduodenal damage induced by antiblastic drugs during antiblastic polychemotherapy. Methods. A heterogeneous group of cancer patients was monitored from January 1984 to December 1999 (293 males and 204 females), aged between 36 and 80 years old, all of whom were undergoing antineoplastic polychemotherapy. Preventive treatment with ranitidine at a dose of 300 mg/die per os in a single evening bolus continued through the entire period of antiblastic treatment ranging from a minimum of six months to one year or more. The study was carried out in the General Surgery Department of Valdichiana Senese, Local Health Unit 7 in Siena and in the Department of Surgical Oncology at the University of Catania. The study consisted of a clinical and instrumental follow-up using esophagogastroduodenoscopy at the time patients were enrolled and at 3, 6 and 12 months, or at the end of treatment if longer. Results. Ranitidine was useful and could significantly reduce the harmful gastric effects of antiblastic drugs, as has been extensively shown by the literature. These drugs can lead to the suspension of treatment owing to intolerance or even death. In this study ranitidine reduced the damaging effects on the upper digestive tract in respectively 78% of the cases treated compared to 22% of non-responders. Conclusions. The action of ranitidine made antiblastic treatment more acceptable by mitigating or even blocking the damaging effects on the stomach and duodenum, leading to an improved quality of life for cancer patients.

KW - Antineoplastic agents therapeutic use

KW - Antineoplastic agents, combined

KW - Ranitidine

UR - http://www.scopus.com/inward/record.url?scp=0034483670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034483670&partnerID=8YFLogxK

M3 - Articolo

C2 - 16498377

AN - SCOPUS:0034483670

VL - 46

SP - 155

EP - 164

JO - Minerva Gastroenterologica

JF - Minerva Gastroenterologica

SN - 0026-4776

IS - 3

ER -